Defiance ETFs’s Novo Nordisk NVO Stock Holding History

Defiance ETFs’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2,192,592	Closed	-$80.6M	–	406
2026 Q1	$80.6M	Buy	+2,192,592	New	+$104M	1.15%	15

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Defiance ETFs's NVO Position: Q2 2026 in Review

Defiance ETFs sold out of Novo Nordisk (NVO) in Q2 2026, closing a stake of 2,192,592 shares — an estimated $80.6M sold.

Defiance ETFs first reported a position in NVO in Q1 2026 and held it in 1 quarter. The position peaked at $80.6M in Q1 2026. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

Defiance ETFs reported no remaining Novo Nordisk position as of Q2 2026 after selling out during the quarter.
Defiance ETFs sold 2,192,592 Novo Nordisk shares in Q2 2026, an estimated $80.6M.
Defiance ETFs first reported a position in Novo Nordisk in Q1 2026 and held it in 1 quarter.
Defiance ETFs's Novo Nordisk position peaked at $80.6M in Q1 2026.
1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Defiance ETFs's 13F filing for Q2 2026, filed 14 Aug 2026.